WO2007075799A3 - Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile - Google Patents

Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile Download PDF

Info

Publication number
WO2007075799A3
WO2007075799A3 PCT/US2006/048629 US2006048629W WO2007075799A3 WO 2007075799 A3 WO2007075799 A3 WO 2007075799A3 US 2006048629 W US2006048629 W US 2006048629W WO 2007075799 A3 WO2007075799 A3 WO 2007075799A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
systems
methods
pharmacokinetic profile
corticosteroids
Prior art date
Application number
PCT/US2006/048629
Other languages
French (fr)
Other versions
WO2007075799A2 (en
Inventor
Malcolm R Hill
Original Assignee
Tika Laekemedel Ab
Malcolm R Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tika Laekemedel Ab, Malcolm R Hill filed Critical Tika Laekemedel Ab
Priority to JP2008547496A priority Critical patent/JP2009524590A/en
Priority to EP06847837A priority patent/EP1973550A2/en
Priority to CA002634398A priority patent/CA2634398A1/en
Priority to BRPI0620225-0A priority patent/BRPI0620225A2/en
Publication of WO2007075799A2 publication Critical patent/WO2007075799A2/en
Publication of WO2007075799A3 publication Critical patent/WO2007075799A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic profile of the corticosteroid as compared to conventional inhalable therapies.
PCT/US2006/048629 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile WO2007075799A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008547496A JP2009524590A (en) 2005-12-20 2006-12-19 Methods and systems for delivering corticosteroids with improved pharmacokinetic profiles
EP06847837A EP1973550A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
CA002634398A CA2634398A1 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
BRPI0620225-0A BRPI0620225A2 (en) 2005-12-20 2006-12-19 methods and systems for the distribution of corticosteroids having an increased pharmacokinetic profile

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US75233205P 2005-12-20 2005-12-20
US75273505P 2005-12-20 2005-12-20
US75276505P 2005-12-20 2005-12-20
US60/752,765 2005-12-20
US60/752,735 2005-12-20
US60/752,332 2005-12-20
US77399806P 2006-02-15 2006-02-15
US77399906P 2006-02-15 2006-02-15
US60/773,999 2006-02-15
US60/773,998 2006-02-15
US82009406P 2006-07-21 2006-07-21
US82009206P 2006-07-21 2006-07-21
US82009606P 2006-07-21 2006-07-21
US60/820,094 2006-07-21
US60/820,096 2006-07-21
US60/820,092 2006-07-21

Publications (2)

Publication Number Publication Date
WO2007075799A2 WO2007075799A2 (en) 2007-07-05
WO2007075799A3 true WO2007075799A3 (en) 2009-01-15

Family

ID=38218568

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2006/048630 WO2007075800A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids
PCT/US2006/048927 WO2007075963A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids
PCT/US2006/048735 WO2007075859A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids having an increased lung deposition
PCT/US2006/048628 WO2007075798A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an increased lung deposition
PCT/US2006/048631 WO2007075801A2 (en) 2005-12-20 2006-12-19 Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile
PCT/US2006/048629 WO2007075799A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile

Family Applications Before (5)

Application Number Title Priority Date Filing Date
PCT/US2006/048630 WO2007075800A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids
PCT/US2006/048927 WO2007075963A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids
PCT/US2006/048735 WO2007075859A2 (en) 2005-12-20 2006-12-19 Systems and methods for the delivery of corticosteroids having an increased lung deposition
PCT/US2006/048628 WO2007075798A2 (en) 2005-12-20 2006-12-19 Methods and systems for the delivery of corticosteroids having an increased lung deposition
PCT/US2006/048631 WO2007075801A2 (en) 2005-12-20 2006-12-19 Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile

Country Status (5)

Country Link
EP (6) EP1971349A2 (en)
JP (6) JP2009524590A (en)
BR (1) BRPI0620225A2 (en)
CA (2) CA2634398A1 (en)
WO (6) WO2007075800A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN101911139B (en) * 2007-11-16 2013-03-20 粒子监测系统有限公司 System and method for calibration verification of an optical particle counter
CA2739353A1 (en) * 2008-10-10 2010-04-15 Schering Corporation Corticosteroid compositions and methods of treatments thereof
US20150202308A1 (en) * 2014-01-17 2015-07-23 Nephron Pharmaceuticals Corporation Budesonide formulation
NZ724902A (en) * 2014-03-28 2023-03-31 Univ Liege Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
EP2923702A1 (en) * 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
US11672781B2 (en) 2018-05-07 2023-06-13 Prana Biosciences Inc Metaxalone formulations
EP3906263A4 (en) 2019-01-03 2022-08-31 Underdog Pharmaceuticals, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
CN113491677B (en) * 2020-03-18 2023-09-26 南京知和医药科技有限公司 Novel medicinal antiviral drug inhalant preparation and preparation method thereof
WO2022217029A1 (en) * 2021-04-09 2022-10-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027845A1 (en) * 2001-01-31 2003-02-06 Pfizer Inc. Ether derivatives useful as inhibitors of PDE4 isozymes
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
WO2005065649A1 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid
US20050222111A1 (en) * 1997-12-31 2005-10-06 Astrazeneca Ab, A Sweden Corporation Method for treating a respiratory disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
CN103405405A (en) * 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 Compositions and methods of delivery of pharmacological agents
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
NZ547389A (en) * 2003-11-21 2009-11-27 Combinatorx Inc Combinations of a compound such as ibudilast and a corticosteroid for the treatment of inflammatory disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222111A1 (en) * 1997-12-31 2005-10-06 Astrazeneca Ab, A Sweden Corporation Method for treating a respiratory disease
US20030027845A1 (en) * 2001-01-31 2003-02-06 Pfizer Inc. Ether derivatives useful as inhibitors of PDE4 isozymes
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
WO2005065649A1 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid

Also Published As

Publication number Publication date
WO2007075798A3 (en) 2008-11-20
WO2007075859A3 (en) 2008-12-11
WO2007075801A3 (en) 2008-12-31
EP1971346A2 (en) 2008-09-24
WO2007075800A2 (en) 2007-07-05
JP2009520828A (en) 2009-05-28
WO2007075800A3 (en) 2008-11-20
WO2007075798A2 (en) 2007-07-05
JP2009520827A (en) 2009-05-28
EP1971345A2 (en) 2008-09-24
EP1973550A2 (en) 2008-10-01
JP2009520823A (en) 2009-05-28
EP1971349A2 (en) 2008-09-24
EP1971347A2 (en) 2008-09-24
WO2007075798A9 (en) 2007-08-23
WO2007075963A2 (en) 2007-07-05
JP2009520821A (en) 2009-05-28
WO2007075801A2 (en) 2007-07-05
EP1971348A2 (en) 2008-09-24
CA2634398A1 (en) 2007-07-05
WO2007075859A2 (en) 2007-07-05
CA2634413A1 (en) 2007-07-05
WO2007075963A3 (en) 2008-11-27
JP2009524590A (en) 2009-07-02
JP2009520822A (en) 2009-05-28
BRPI0620225A2 (en) 2011-11-01
WO2007075799A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2007075799A3 (en) Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
WO2007053698A3 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2007095339A3 (en) Methods of manufacturing corticosteroid solutions
WO2008053221A3 (en) Process for preparing indol- 5 -oxy- quinazoline derivatives and intermediates
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
WO2007042035A3 (en) Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2005074990A3 (en) Methods of preventing and treating sars using low ph respiratory tract compositions
WO2006105401A3 (en) Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
WO2005116086A3 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
WO2008025787A3 (en) Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2007136439A3 (en) Hyperpolarization methods, systems and compositions
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2006131392A8 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
WO2006026747A3 (en) Diphenylethylene compounds and uses thereof
WO2007022384A3 (en) Pyrazine kinase inhibitors
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2007057714A3 (en) Pharmaceutical compositions comprising methotrexate
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2007023243A3 (en) Cleavage of antifolate compounds
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
WO2006133374A3 (en) Methods for treating shock
WO2007133944A3 (en) Topical administration of acyclovir
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
WO2006127321A3 (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680053153.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008547496

Country of ref document: JP

Ref document number: 2634398

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006847837

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6305/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008129649

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0620225

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080620